Treatment of older patients with non-small-cell lung cancer: Walking the therapeutic tightrope

Journal of Clinical Oncology

Volumn 28, Issue 4, 2010, Pages 523-526

  Simon, George R ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; ERLOTINIB; PACLITAXEL; PLACEBO; ANTINEOPLASTIC AGENT;

AGED; ANOREXIA; ATTRIBUTABLE RISK; BLEEDING; BONE MARROW SUPPRESSION; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CREATININE CLEARANCE; DEHYDRATION; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG ACTIVITY; DRUG SAFETY; DRUG TARGETING; EDITORIAL; FATIGUE; GROUPS BY AGE; HUMAN; LUNG NON SMALL CELL CANCER; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RASH; RISK ASSESSMENT; STOMATITIS; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; LUNG TUMOR; MIDDLE AGED; NOTE;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MIDDLE AGED;

EID: 77449097943     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.3773     Document Type: Editorial

References (30)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. CA Cancer J Clin 59:225-249, 2009
2. Yancik R: Population aging and cancer: A cross-national concern. Cancer J 11:437-441, 2005
3. Chrischilles EA, Pendergast JF, Kahn KA, et al: Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 28:620-627, 2010
4. Frasci G, Lorusso V, Panza N, et al: Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer: A Southern Italy Cooperative Oncology Group (SICOG) phase III trial. Lung Cancer 34:S65-S69, 2001 (suppl 4) (Pubitemid 33115260)
5. Gridelli C: The ELVIS trial: A phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: Elderly Lung Cancer Vinorelbine Italian Study. Oncologist 6:4-7, 2001 (suppl 1) (Pubitemid 32155180)
6. Gridelli C, Perrone F, Gallo C, et al: Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95:362-372, 2003
7. Langer CJ, Manola J, Bernardo P, et al: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94:173-181, 2002 (Pubitemid 34162751)
8. Simon GR, Extermann M, Chiappori A, et al: Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older. Cancer 112:2021-2029, 2008 (Pubitemid 351574078)
9. Kim HJ, Kim TG, Lee HJ, et al: A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer. Lung Cancer 2009
10. Yang L, Fujimoto J, Qiu D, et al: Trends in cancer mortality in the elderly in Japan, 1970-2007. Ann Oncol 2009
11. Yuh YJ, Lee HR, Kim SR: Gemcitabine and carboplatin combination chemotherapy for elderly patients with advanced non-small cell lung cancer: A feasibility study. Cancer Res Treat 40:116-120, 2008
12. Cohen MH, Johnson JR, Chen YF, et al: FDA drug approval summary: Erlotinib (Tarceva) tablets. Oncologist 10:461-466, 2005
13. Cohen MH, Gootenberg J, Keegan P, et al: FDA drug approval summary: Bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12:713-718, 2007 (Pubitemid 47036205)
14. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005
15. Wheatley-Price P, Ding K, Seymour L, et al: Erlotinib for advanced non-small-cell lung cancer in the elderly: An analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR. 21. J Clin Oncol 26:2350-2357, 2008
16. Sotaniemi EA, Arranto AJ, Pelkonen O, et al: Age and cytochrome P450-linked drug metabolism in humans: An analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 61:331-339, 1997
17. Cohen MH, Johnson JR, Wang YC, et al: FDA drug approval summary: Pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist 10:363-368, 2005
18. Hanna N, Shepherd FA, Fossella FV, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597, 2004
19. Scagliotti GV, Ceppi P, Capelletto E, et al: Updated clinical information on multitargeted antifolates in lung cancer. Clin Lung Cancer 10:S35-S40, 2009 (suppl 1)
20. Mita AC, Sweeney CJ, Baker SD, et al: Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol 24:552-562, 2006
21. Verhave JC, Fesler P, Ribstein J, et al: Estimation of renal function in subjects with normal serum creatinine levels: Influence of age and body mass index. Am J Kidney Dis 46:233-241, 2005 (Pubitemid 41040351)
22. Lindeman RD, Tobin J, Shock NW: Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 33:278-285, 1985 (Pubitemid 15087125)
23. Fliser D, Bischoff I, Hanses A, et al: Renal handling of drugs in the healthy elderly: Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. Eur J Clin Pharmacol 55:205-211, 1999 (Pubitemid 29244648)
24. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006 (Pubitemid 44917502)
25. Ramalingam SS, Dahlberg SE, Langer CJ, et al: Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 26:60-65, 2008
26. Marley SB, Lewis JL, Davidson RJ, et al: Evidence for a continuous decline in haemopoietic cell function from birth: Application to evaluating bone marrow failure in children. Br J Haematol 106:162-166, 1999
27. Repetto L: Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol 1:18-24, 2003
28. Balducci L, Repetto L: Increased risk of myelotoxicity in elderly patients with non-Hodgkin lymphoma. Cancer 100:6-11, 2004
29. Smith TJ, Khatcheressian J, Lyman GH, et al: 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 24:3187-3205, 2006
30. National Cancer Institute: FDA approval for pemetrexed disodium. http://www.cancer.gov/cancertopics/druginfo/fda-pemetrexed-disodium